CAJ | 학술논문

目的探讨N-乙酰半胱氨酸对特发性肺纤维化患者血清转化生长因子β1(TGF-β1)和白细胞介素13(IL-13)的影响.方法 122例特发性肺纤维化患者按就诊顺序分2组.治疗组62例,每天口服强的松0.5 mg/kg,4周后减半维持,同时口服N-乙酰半胱氨酸600 mg/次,3次/d.对照组60例每天口服强的松0.5 m/kg,4周后减半维持,疗程均为3个月.观察2组患者临床表现,肺高分辨率cT表现,血气分析,肺功能改变及症状缓解时间.TGF-β1和IL-13在治疗前后被测定.结果经治疗治疗组改善58例(93.5%);对照组48例(80.0%),2组差异有统计学意义(P<0.05).治疗组治疗后的TGF-β1和IL-13分别为(46.8±19.7)μg/L、(76.9±20.1)g/L均较治疗前[(118.1±31.2)μg/L与(152.4±28.4)g/L]有明显改善,与对照组[(86.3±29.6)μg/L、(121.5±22.5)g/L]相比,差异有统计学意义(P<0.05).结论 N-乙酰半胱氨酸改善症状和体征可能通过改善TGF-β1和IL-13而达到.
목적 탐토N-을선반광안산대특발성폐섬유화환자혈청전화생장인자β1(TGF-β1)화백세포개소13(IL-13)적영향.방법 122례특발성폐섬유화환자안취진순서분2조.치료조62례,매천구복강적송0.5 mg/kg,4주후감반유지,동시구복N-을선반광안산600 mg/차,3차/d.대조조60례매천구복강적송0.5 m/kg,4주후감반유지,료정균위3개월.관찰2조환자림상표현,폐고분변솔cT표현,혈기분석,폐공능개변급증상완해시간.TGF-β1화IL-13재치료전후피측정.결과 경치료치료조개선58례(93.5%);대조조48례(80.0%),2조차이유통계학의의(P<0.05).치료조치료후적TGF-β1화IL-13분별위(46.8±19.7)μg/L、(76.9±20.1)g/L균교치료전[(118.1±31.2)μg/L여(152.4±28.4)g/L]유명현개선,여대조조[(86.3±29.6)μg/L、(121.5±22.5)g/L]상비,차이유통계학의의(P<0.05).결론 N-을선반광안산개선증상화체정가능통과개선TGF-β1화IL-13이체도.
Objective To investigate the significance of expression of transforming growth factor β1 (TGF-β1)and interleukin 13 in patients with idiopathic pulmonary fibrosis(IPF) though Fluimucil. Methods One hun-dred and twenty-two IPF patients were randomly divided into two groups. Treatment group included 62 cases treated with prednisone 0.5 mg/kg per day orally and the dosage was reduced 50% 4 weeks later and Fluimucil 600 mg three times per day. Control group included 60 cases receiving prednisone 0.5 mg/kg per day orally and a half dos-age 4 weeks later. The clinical manifestation, pulmonary function testing, high-resolution chest CT, arterial blood gas analysis were observed before and 3 months after treatment. Results After treatment of 3 months, the improve-ment rate of symptoms and signs in the treatment group was superior to that in the control group (P < 0.05 ). The se-rum levels of TGF-β1 and IL-13 in the treatment group were decreased significantly(P < 0.05 ). Conclusion Flu-imucil can improve symptoms and signs of the patient with pulmonary interstitial fibrosis via decreasing TGF-β1 and IL-13.